Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. - Wikidata - wikimedia - TriplyDB

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

http://www.wikidata.org/entity/Q35704498

about

Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis Pathogenesis of Focal Segmental Glomerulosclerosis Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.Focal Segmental Glomerulosclerosis.What are we missing in the clinical trials of focal segmental glomerulosclerosis?Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?Investigational drugs in development for focal segmental glomerulosclerosis.Clinical trials in minimal change disease.

P2860

Q26740540-0C4CF041-9892-474A-8C8F-7E508B2BD04A Q26747221-962B52EF-4BC9-4666-AB3D-A1CFA680C1AC Q26752836-1FC9E1B9-D934-4840-AD64-091D3E2C0FDB Q26753833-F9ED2833-F3FA-4377-B461-71F5F3BA3B91 Q28067299-232814C2-B6E7-4CD8-94AC-C06945E12C31 Q36789030-DBBD3237-F516-46E6-8C1C-3E081ED9CADB Q37217446-60CACE1F-0E2F-4836-A606-01C260752588 Q38805701-30BBF684-D019-41F7-9321-3959882049F8 Q38938623-FF825ED8-B4BF-4BA7-A335-9297EE940677 Q39229298-C3245F24-B9AD-4DC1-BAC0-E0E1C3FA5726 Q39335899-9233B444-7754-4EC0-8F1E-BDEA0A349630 Q41688065-12D93F67-EB9E-40D4-85FD-8560B224E3C9 Q42688626-5E6684F8-6E43-443F-8CC8-0A56F2BF59A5 Q49772713-D8DA9E6C-12B6-4548-B6B6-0FD244D61AAC Q51066095-FBBB7661-5E72-4022-8F65-C81E25E9258F Q51840896-CD30C606-5173-4617-8EB6-BA72A6377445 Q53368686-81BE6346-9499-49F2-B5F6-1688DF467C74

P2860

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

http://www.wikidata.org/entity/Q35704498

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy of galactose and adal ...... the font clinical trial group.

@ast

Efficacy of galactose and adal ...... the font clinical trial group.

@en

type

label

Efficacy of galactose and adal ...... the font clinical trial group.

@ast

Efficacy of galactose and adal ...... the font clinical trial group.

@en

prefLabel

Efficacy of galactose and adal ...... the font clinical trial group.

@ast

Efficacy of galactose and adal ...... the font clinical trial group.

@en

P1433

Q35704498-10257A9C-CE3D-4361-952A-24A44470CAD1

P1476

Q35704498-399D31BC-3302-4F7F-816F-7954E244F5A3

P2093

Q35704498-16A219EA-3639-4E1C-817C-C369566745DA

Q35704498-5185703E-B4A9-41A2-ADCD-CD6927F55996

Q35704498-AE2A7467-C3CC-4D04-9950-D9203B5C40D9

Q35704498-B640A9EB-7435-4505-856A-F541AD4C7DB5

Q35704498-C0EDE3A9-2905-47CC-8A3B-CCF736B346AD

Q35704498-C4F5BC7B-89F2-40D0-9F67-D1087352C011

Q35704498-D7AD0AE4-EA7B-45F8-BEA9-C1826D19AFAF

Q35704498-DCF303C1-424C-4C63-9884-F511A40BFA6D

Q35704498-E4ECCC76-77F0-4FB6-A75A-50EF7164ADE9

Q35704498-E70D5D01-32A4-4709-AD18-B00BB130315C

P2860

Q35704498-0D6D5DC6-B244-4189-AB99-3962839104AD

Q35704498-1B3ECAFF-A98A-4BDD-9995-EA2E137F8AD7

Q35704498-1E673860-1460-4877-8234-CE40C8F00C85

Q35704498-27CD452E-3599-40BF-BB6D-E8CE1125B7A1

Q35704498-2844A57A-2672-4C1B-A0CE-82BD3ACFE760

Q35704498-2A9BF51B-37D0-4D48-A375-BAF71A7AD07D

Q35704498-2E19097E-20C3-4050-BB33-FC241C392B08

Q35704498-33A17955-3EF7-48BB-8DB6-C60285A3117E

Q35704498-34807DCA-0C95-4F4D-BE1D-D4FAAB29EA98

Q35704498-4157A276-606D-44EB-A3E6-FCD744C89506

P304

Q35704498-3A7CB254-4C53-4827-A48A-38BD0C6EA4D9

P31

Q35704498-37580DED-3A7D-4919-8E78-815F171A6E61

P356

Q35704498-7C5D8CB7-B6E2-4B35-B8DB-FC6A969327D0

P478

Q35704498-EC6AA849-F317-4283-A99C-F8B5105AA2F0

P50

Q35704498-5D97FD14-7A8C-4494-892E-E78221C3C356

Q35704498-6865CB49-F3C6-4941-B044-2187647F0231

Q35704498-B237E1F9-BDFA-4839-B978-71CA19C8025E

P577

Q35704498-2B8B4A7D-846B-4FA3-ADC1-CF41A334B462

P5875

Q35704498-DEF0F198-20D7-45BD-9C45-0D1682785A3D

P698

Q35704498-4E10295E-D4F5-41C5-A49B-B58A53C3ACC9

P921

Q35704498-70E3B952-7C36-4639-8263-D4B2FD8208E5

P932

Q35704498-6D0D4ED7-A8B5-43F5-9E67-61E0C0B6CD4C

P356

S12882-015-0094-5

P1433

P1476

Efficacy of galactose and adal ...... the font clinical trial group.

@en

P2093

Changli Wei

http://www.w3.org/2001/XMLSchema#string

Daniel T Stein

http://www.w3.org/2001/XMLSchema#string

Emily Herreshoff

http://www.w3.org/2001/XMLSchema#string

Jennifer Gassman

http://www.w3.org/2001/XMLSchema#string

Jochen Reiser

http://www.w3.org/2001/XMLSchema#string

Michael Somers

http://www.w3.org/2001/XMLSchema#string

Milena Radeva

http://www.w3.org/2001/XMLSchema#string

Mukut Sharma

http://www.w3.org/2001/XMLSchema#string

Suzanne Vento

http://www.w3.org/2001/XMLSchema#string

Tarak Srivastava

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Analysis of concentration and (13)C enrichment of D-galactose in human plasma

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

P304

111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12882-015-0094-5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Howard Trachtman

Debbie S Gipson

Jennifer Gassman

P577

2015-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281820645

http://www.w3.org/2001/XMLSchema#string

P698

26198842

http://www.w3.org/2001/XMLSchema#string

P921

P932

4511259

http://www.w3.org/2001/XMLSchema#string